Dario-Alessandro Dornbierer

Dario-Alessandro Dornbierer has a diverse and extensive work experience. Dario-Alessandro is the Co-Founder and CSO of Reconnect Labs since May 2021, as well as the Co-Founder and CSO of Galventa AG since November 2017. Dario-Alessandro also held various fellowship roles at the University of Zurich, including SNF Bridge PoC Fellowship from October 2020 to September 2021 and the UZH Entrepreneur Fellowship from April 2019 to September 2020. Prior to that, they worked as an MA Student at ETH Zurich from September 2017 to April 2019 and obtained a Dr. sc. ETH Zurich degree from ETH Zurich. Additionally, Dario-Alessandro gained research experience as a Research Assistant at the University of Basel from October 2014 to April 2015 and as a Research Assistant at the University of Zurich from February 2014 to August 2014. Furthermore, they worked as a Swiss Federal Pharmacist at Apotheke Hotz from October 2012 to June 2013. Dario-Alessandro started their academic journey as an MSc Student at the University of Zurich from October 2011 to July 2012 and completed their BSc degree at ETH Zurich from 2007 to 2011.

Dario-Alessandro Dornbierer's education history reveals a steady progression in their academic pursuits. Dario-Alessandro began their journey at ETH Zürich in 2007 and completed their Bachelor of Science degree in Pharmaceutical Sciences in 2011. This foundational undergraduate education likely laid the groundwork for their future studies and career.

Motivated to further their knowledge, Dornbierer pursued a Master of Science degree in Pharmaceutical Sciences at ETH Zürich from 2011 to 2013. This advanced program likely provided him with a deeper understanding of the subject and prepared him for more specialized research and development work.

After completing their Master's degree, Dornbierer continued to advance their academic career by joining ETH Zürich for their PhD in Neuroscience, which spanned from 2015 to 2018. During this period, they likely conducted extensive research in the field of neuroscience, contributing to the existing body of knowledge in this area.

Seeking to expand their expertise further, Dornbierer pursued a PostDoc at the University of Zurich from 2018 to 2020. During this time, they focused on the specific area of Psychedelic Research and Therapy Development. Through their work, they likely explored the potential applications and therapeutic benefits of psychedelic substances, contributing to the emerging field of psychedelic research.

Overall, Dario-Alessandro Dornbierer's education history demonstrates a progressive path, starting with a solid foundation in pharmaceutical sciences and culminating in specialized research roles in neuroscience and psychedelic research and therapy development.